NCT06585319View on ClinicalTrials.gov

Pirfenidone LP or Collagen-polyvinylpyrrolidone in COVID-19

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 1, 2020

Primary Completion Date

June 30, 2021

Study Completion Date

August 31, 2024

Conditions
COVID 19
Interventions
DRUG

Collagen-polyvinylpyrrolidone

2 ml intramuscular q24 h

DRUG

Pirfenidone 1200 mg

1,200 mg of oral q12 h

Trial Locations (1)

50120

Monica Pretelini Saenz Maternal Perinatal Hospital, Toluca

All Listed Sponsors
lead

Materno-Perinatal Hospital of the State of Mexico

OTHER

NCT06585319 - Pirfenidone LP or Collagen-polyvinylpyrrolidone in COVID-19 | Biotech Hunter | Biotech Hunter